Mukesh Pandey

Mukesh Pandey

Auto-generated profile, based on publicly available information

Mukesh Pandey

Department of Pharmaceutics, Delhi Institute of Pharmaceutical Sciences and Research, India

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 October 2020 in Current Pharmaceutical Design
Verified
Journal Article
Closed access
PDF file
BKBhumika Kumar
Bhumika Kumar
MPMukesh Pandey
Mukesh Pandey
FPFaheem Hyder Pottoo
Faheem Hyder Pottoo
FFFaizana Fayaz
Faizana Fayaz
ASAnjali Sharma
Anjali Sharma
PSP.K. Sahoo
P.K. Sahoo
Parkinson’s disease is one of the most severe progressive neurodegenerative disorders, having a mortifying effect on the health of millions of people around the globe. The neural cells producing dopamine in the substantia nigra of the brain die out. This leads to symptoms like hypokinesia, rigidity, bradykinesia, and rest tremor. Parkinsonism cannot be cured, but the symptoms can be reduced with the intervention of medicinal drugs, surgical treatments, and physical therapies. Delivering drugs to the brain for treating Parkinson’s disease is very challenging. The blood-brain barrier acts as a highly selective semi-permeable barrier, which refrains the drug from reaching the brain. Conventional drug delivery systems used for Parkinson’s disease do not readily cross the blood barrier and further lead to several side-effects. Recent advancements in drug delivery technologies have facilitated drug delivery to the brain without flooding the bloodstream and by directly targeting the neurons. In the era of Nanotherapeutics, liposomes are an efficient drug delivery option for brain targeting. Liposomes facilitate the passage of drugs across the blood-brain barrier, enhances the efficacy of the drugs, and minimize the side effects related to it. The review aims at providing a broad updated view of the liposomes, which can be used for targeting Parkinson’s disease.

14 September 2021 in Combinatorial Chemistry & High Throughput Screening
Verified
Journal Article
Closed access
PDF file
JMJayanti Mishra
Jayanti Mishra
BKBhumika Kumar
Bhumika Kumar
MPMukesh Pandey
Mukesh Pandey
FPFaheem Hyder Pottoo
Faheem Hyder Pottoo
FFFaizana Fayaz
Faizana Fayaz
PSPravat K. Sahoo
Pravat K. Sahoo
Background: Alzheimer’s disease is an irreversible, progressive brain disorder manifested with symptoms like loss of memory (known as dementia), personality changes, loss of cognition, impaired movement, confusion, deteriorated planning and thought process. Neurodegeneration in Alzheimer’s disease is the result of deposition of protein beta-amyloid that forms plaques and another protein called tau, forming tangles that prevent proper functioning of nerve cells in the brain. Methods: The goal of the review was to comprehensively study the utilization of nanotechnology and the role that carbon nanotubes can play as a drug delivery system for amelioration of Alzheimer’s disease. Results: Nanotechnology is one of the most researched domains of modern science. It contributes significantly to therapeutics by facilitating drug therapy to reach the target sites, which are otherwise difficult to reach with conventional drug delivery systems. Carbon nanotubes are the allotropes of carbon in which several carbon atoms bind with each other to form a cylindrical or a tube-like structure. The carbon nanotubes possess several unique qualities, which confer them with a high potential of being utilized as an efficient drug delivery system. They offer high drug loading and can readily cross the toughest biological barriers like the BBB. Carbon nanotubes also facilitate the passage of drugs to the brain via the olfactory route, which further helps in restoring normal autophagy, thus preventing the elimination of autophagic chemicals. They can carry a vast range of cargos, including drugs, antigens, genetic materials, and biological macromolecules. Conclusion: Carbon nanotubes are a highly promising drug delivery system for anti-Alzheimer’s drugs. They have the potential of overcoming the various biological barriers like the BBB. However, more extensive research is required so as to set up a firm base for the development of advanced commercial products based on carbon nanotubes for the treatment of Alzheimer’s disease.

1 January 2020
Verified
Book Chapter
Closed access
MPMukesh Pandey
Mukesh Pandey
SSShakir Saleem
Shakir Saleem
HNHimani Nautiyal
Himani Nautiyal
FPFaheem Hyder Pottoo
Faheem Hyder Pottoo
MJMd Noushad Javed
Md Noushad Javed
PTEN-induced kinase 1 (PINK1), a mitochondrial serine/threonine-protein kinase encoded by the PINK1 gene, is thought to protect cells from stress-induced mitochondrial dysfunction. The activity of PINK1 facilitates the binding of Parkin protein with depolarized mitochondria to induce autophagy. Mutations of PINK1causes a type of autosomal recessive early-onset Parkinson's disease. Cell depends on the surveillance systems or mechanisms like protein quality control to handle the alterations in the proteins that are induced because of these mutations. These mutant proteins are found to be pathogenic and are reported to be related to various neurodegenerative disorders. This chapter focuses on the role of PINK1/Parkin in mitochondria quality control and its subsequent effect in neurodegeneration.

1 October 2021 in CNS & Neurological Disorders - Drug Targets
Verified
Journal Article
Closed access
PDF file
BKBhumika Kumar
Bhumika Kumar
MPMukesh Pandey
Mukesh Pandey
AMAshwini Kumar Mishra
Ashwini Kumar Mishra
ASAnjali Sharma
Anjali Sharma
FFFaizana Fayaz
Faizana Fayaz
FPFaheem Hyder Pottoo
Faheem Hyder Pottoo
Dementia is a diverse category of chronic and progressive disorder, which is commonly associated with a loss of memory, difficulty in judgment, impaired language, cognitive impairment, and various other symptoms that affect a person’s daily routine life and social life. Dementia affects about 50 million people around the globe. Dementia exists in varied forms and is associated with various neurodegenerative disorders. Alzheimer's disease is the most common form, which accords for about 60% of thecases. Abnormal agglomeration of proteins in the brain has been linked to the pathogenesis of dementia. Autophagy is a necessary protein clearance mechanism, which is dependent on lysosomes. It is a basic physiological process that performs the crucial function of maintaining protein homeostasis within the cells. The autophagic dysfunction in dementia further complicates the disease by hampering the degradation and removing abnormal pathogenic proteins. In order to understand autophagic dysfunction, it is essential to know the genetics of autophagy as well as the mutations This understanding at the genetic level helps definethe relationship between dementia and autophagic dysfunction for developing the potential remedies for the treatment of dementia.

1 January 2020
Verified
Book Chapter
Closed access
OKOzaifa Kareem
Ozaifa Kareem
GBGhulam Nabi Bader
Ghulam Nabi Bader
FPFaheem Hyder Pottoo
Faheem Hyder Pottoo
MAMohd. Amir
Mohd. Amir
HBHarshita Barkat
Harshita Barkat
MPMukesh Pandey
Mukesh Pandey
Beclin1 is the mammalian orthologue of yeast Atg6/vacuolar protein sorting-30 (VPS30). Beclin1 interacts with various biological macromolecules like ATG14, BIF-1, NRBF2, RUBICON, UVRAG, AMBRA1, HMGB1, PINK1, and PARKIN. Such interactions promote Beclin1-PI3KC3 complex formation. Autophagy is blocked in apoptosis owing to the breakdown of Beclin1 by caspase whereas autophagy induction inhibits effector caspase degradation, therefore, blocks apoptosis. Thus, the Beclin1 is an essential biomolecular species for cross-regulation between autophagy and apoptosis. Various studies carried out in neurodegenerative animal models associated with aggregated proteins have confirmed that multifunctional Beclin1 protein is necessary for neuronal integrity. The role of Beclin1 protein has been investigated and was reported in various human neurodegeneration disorders. This chapter aims to provide an insight into the role of Beclin1 in the development of neurodegenerative disorders.